Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women, Science, vol.329, issue.5996, pp.1168-1174, 2010. ,
DOI : 10.1126/science.1193748
Prevention of HIV-1 Infection with Early Antiretroviral Therapy, New England Journal of Medicine, vol.365, issue.6, pp.493-505, 2011. ,
DOI : 10.1056/NEJMoa1105243
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial, The Lancet, vol.369, issue.9562, pp.657-666, 2007. ,
DOI : 10.1016/S0140-6736(07)60313-4
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women, New England Journal of Medicine, vol.367, issue.5, pp.399-410, 2012. ,
DOI : 10.1056/NEJMoa1108524
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand, New England Journal of Medicine, vol.361, issue.23, pp.2209-2220, 2009. ,
DOI : 10.1056/NEJMoa0908492
RV 144 Update: Vaccination with ALVAC and AIDSVAC to prevent HIV-1 infection in Thai adults, 17th Conference on Retroviruses and Opportunistic Infections, 2010. ,
HIV/AIDS preventive vaccine ???prime-boost??? phase III trial: foundations and initial lessons learned from Thailand, AIDS, vol.20, issue.11, pp.1471-1479, 2006. ,
DOI : 10.1097/01.aids.0000237362.26370.f8
The Road to an Effective HIV Vaccine, New England Journal of Medicine, vol.366, issue.14, pp.1343-1344, 2012. ,
DOI : 10.1056/NEJMe1202492
Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study, The Lancet Infectious Diseases, vol.11, issue.7, pp.507-515, 2011. ,
DOI : 10.1016/S1473-3099(11)70098-6
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine, New England Journal of Medicine, vol.369, issue.22, p.369, 2013. ,
DOI : 10.1056/NEJMoa1310566
The design and evaluation of HIV-1 vaccines, AIDS, vol.26, issue.10, pp.1293-1302 ,
DOI : 10.1097/QAD.0b013e32835474d2
HIV-1 Vaccines and Adaptive Trial Designs, Science Translational Medicine, vol.3, issue.79, pp.79-92, 2011. ,
DOI : 10.1126/scitranslmed.3001863
Designing Tomorrow's Vaccines, New England Journal of Medicine, vol.368, issue.6, pp.551-560, 2013. ,
DOI : 10.1056/NEJMra1204186
Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines, Journal of Clinical Oncology, vol.19, issue.6, pp.1848-185419, 2001. ,
DOI : 10.1200/JCO.2001.19.6.1848
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Novel directions in HIV-1 vaccines revealed from clinical trials, Current Opinion in HIV and AIDS, vol.8, issue.5, pp.421-431, 2013. ,
DOI : 10.1097/COH.0b013e3283632c26
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens, Statistical Communications in Infectious Diseases, vol.3, issue.1, p.4, 2011. ,
DOI : 10.2202/1948-4690.1037
Statistical evaluation of HIV vaccines in early clinical trials, Contemporary Clinical Trials, vol.27, issue.2, pp.147-160, 2006. ,
DOI : 10.1016/j.cct.2005.11.008
The role of IFN-?? Elispot assay in HIV vaccine research, Nature Protocols, vol.61, issue.4, pp.461-469, 2009. ,
DOI : 10.1186/1479-5876-3-20
Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate, PLoS ONE, vol.27, issue.11, p.13983, 2010. ,
DOI : 10.1371/journal.pone.0013983.s005
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02), Vaccine, vol.29, issue.46, pp.8309-8316, 2011. ,
DOI : 10.1016/j.vaccine.2011.08.098
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects, Journal of Infectious Diseases, vol.207, issue.5, pp.749-758, 2013. ,
DOI : 10.1093/infdis/jis753
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity, Vaccine, vol.25, issue.11, pp.2120-2127, 2007. ,
DOI : 10.1016/j.vaccine.2006.11.016
Broad Immunogenicity of a Multigene, Multiclade HIV???1 DNA Vaccine Boosted with Heterologous HIV???1 Recombinant Modified Vaccinia Virus Ankara, The Journal of Infectious Diseases, vol.198, issue.10, pp.1482-1490, 2008. ,
DOI : 10.1086/592507
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial, The Lancet, vol.381, issue.9871, pp.1021-1028, 2013. ,
DOI : 10.1016/S0140-6736(13)60177-4
Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine, PLoS ONE, vol.5, issue.1, p.8816, 2010. ,
DOI : 10.1371/journal.pone.0008816.s002
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE??, Vaccine, vol.28, issue.5, pp.1209-1216, 2010. ,
DOI : 10.1016/j.vaccine.2009.11.030
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults, Vaccine, vol.30, issue.38, pp.5616-5624, 2012. ,
DOI : 10.1016/j.vaccine.2012.06.084
A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers, AIDS Research and Human Retroviruses, vol.25, issue.11, pp.1107-1116, 2009. ,
DOI : 10.1089/aid.2009.0096
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults, AIDS, vol.20, issue.7, pp.1039-1049, 2006. ,
DOI : 10.1097/01.aids.0000222077.68243.22
DNA vaccines for HIV: challenges and opportunities, Springer Seminars in Immunopathology, vol.74, issue.3, pp.267-279, 2006. ,
DOI : 10.1007/s00281-006-0046-z
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial, AIDS, vol.24, issue.14, pp.2211-2223, 2010. ,
DOI : 10.1097/QAD.0b013e32833ce566
Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU??-Multi-HIVB, in untreated HIV-1 infected subjects, Vaccine, vol.30, issue.27, pp.4046-4054, 2012. ,
DOI : 10.1016/j.vaccine.2012.04.007
Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med, p.7351, 2012. ,
Randomized phase II clinical trials, Cancer Treat Rep, vol.69, pp.1375-1381, 1985. ,
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, Journal of Immunotherapy, vol.30, issue.1, pp.1-15, 2007. ,
DOI : 10.1097/01.cji.0000211341.88835.ae
Participation in two phase II prophylactic HIV vaccine trials in the UK, Vaccine, vol.26, issue.23, pp.2919-2924, 2008. ,
DOI : 10.1016/j.vaccine.2008.03.039
Vaccine Prime???Boost Regimens, The Journal of Infectious Diseases, vol.201, issue.1, pp.132-141, 2010. ,
DOI : 10.1086/648591
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) PloS One, p.21225, 2011. ,
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses, The Journal of Experimental Medicine, vol.3, issue.1, pp.63-77, 2008. ,
DOI : 10.4049/jimmunol.173.10.6274
Designing phase II trials in cancer: a systematic review and guidance, British Journal of Cancer, vol.4, issue.2, pp.194-199, 2011. ,
DOI : 10.1038/bjc.2011.235
Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring, Pharmaceutical Statistics, vol.1, issue.2, pp.170-176, 2012. ,
DOI : 10.1002/pst.510
Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial, PLoS ONE, vol.167, issue.8, p.725, 2007. ,
DOI : 10.1371/journal.pone.0000725.s002
Optimal Priming of Poxvirus Vector-based HIV Vaccine Regimens Requires 3 DNA Injections: Results of the Randomized Multicentre EV03/ANRS Vac20 Phase I/II Trial, 17th Conference on Retroviruses and Opportunistic Infections, 2010. ,
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination, Immunity, vol.33, issue.4, pp.542-554, 2010. ,
DOI : 10.1016/j.immuni.2010.09.011
Immunology and the elusive AIDS vaccine, Nature, vol.321, issue.7286, pp.224-231, 2010. ,
DOI : 10.1038/nature08898
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case???cohort analysis, The Lancet, vol.372, issue.9653, p.372, 1894. ,
DOI : 10.1016/S0140-6736(08)61592-5
One-Sample Multiple Testing Procedure for Phase II Clinical Trials, Biometrics, vol.38, issue.1, pp.143-151, 1982. ,
DOI : 10.2307/2530297
Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group, Clinical Cancer Research, vol.12, issue.7, p.12, 1966. ,
DOI : 10.1158/1078-0432.CCR-05-1136
Sample size tables for exact single-stage phase II designs, pp.859-866, 2001. ,
Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial, Contemporary Clinical Trials, vol.29, issue.4, pp.608-616, 2008. ,
DOI : 10.1016/j.cct.2007.11.005
On the estimation of the binomial probability in multistage clinical trials, Statistics in Medicine, vol.73, issue.6, pp.881-896, 2004. ,
DOI : 10.1002/sim.1653
Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials, Biometrics, vol.51, issue.4, pp.1372-1383, 1995. ,
DOI : 10.2307/2533268
Toxicity-evaluation designs for phase I/II cancer immunotherapy trials, Statistics in Medicine, vol.49, issue.7-8, pp.712-720, 2010. ,
DOI : 10.1002/sim.3799
Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse Events, Medical Decision Making, vol.29, issue.3, pp.343-350, 2009. ,
DOI : 10.1177/0272989X08327332
Continuous Toxicity Monitoring in Phase II Trials in Oncology, Biometrics, vol.42, issue.2, pp.540-545, 2005. ,
DOI : 10.1111/j.1541-0420.2005.00311.x
Group sequential control of overall toxicity incidents in clinical trials ??? non-Bayesian and Bayesian approaches, Statistical Methods in Medical Research, vol.51, issue.1, 2012. ,
DOI : 10.1016/0197-2456(86)90004-8
The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent, Journal of Chronic Diseases, vol.13, issue.4, pp.346-353, 1961. ,
DOI : 10.1016/0021-9681(61)90060-1
Optimal two-stage designs for phase II clinical trials, Controlled Clinical Trials, vol.10, issue.1, pp.1-10, 1989. ,
DOI : 10.1016/0197-2456(89)90015-9
Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials, Journal of Clinical Oncology, vol.23, issue.28, pp.7199-7206, 2005. ,
DOI : 10.1200/JCO.2005.01.149
Group Sequential Methods with Applications to Clinical Trials, 2000. ,
Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm, Statistics in Medicine, vol.51, issue.11, pp.1575-1589, 2001. ,
DOI : 10.1002/sim.713
A predictive probability design for phase II cancer clinical trials, Clinical Trials, vol.14, issue.1, pp.93-106, 2008. ,
DOI : 10.1177/1740774508089279
Alternative designs of phase II trials considering response and toxicity, Contemporary Clinical Trials, vol.28, issue.4, pp.525-531, 2007. ,
DOI : 10.1016/j.cct.2007.03.003
Optimal two-stage designs for clinical trials based on safety and efficacy, Statistics in Medicine, vol.64, issue.7, pp.1023-1032, 2001. ,
DOI : 10.1002/sim.717
Bivariate Sequential Designs for Phase II Trials, Biometrics, vol.51, issue.2, pp.656-664, 1995. ,
DOI : 10.2307/2532952
An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials, Statistics in Medicine, vol.91, issue.4, pp.1648-1664, 2011. ,
DOI : 10.1002/sim.4229
Flexible bivariate phase II clinical trial design incorporating toxicity and response on different schedules, Statistics in Medicine, vol.55, issue.2, pp.470-485, 2013. ,
DOI : 10.1002/sim.5671
Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents, Clinical Cancer Research, vol.17, issue.4, pp.640-646, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-1262
False Positive Rates of Randomized Phase II Designs, Controlled Clinical Trials, vol.20, issue.4, pp.343-352, 1999. ,
DOI : 10.1016/S0197-2456(99)00009-4
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design, Trials, vol.15, issue.1, p.68, 2014. ,
DOI : 10.1016/S0197-2456(99)00009-4
URL : https://hal.archives-ouvertes.fr/inserm-00955157